NASDAQ: NSPRInspiremd Inc Stock
$1.64-0.03 (-1.8%)
Updated May 26, 2023
NSPR Price
$1.64
Fair Value Price
$2.25
Market Cap
$13.70M
52 Week Low
$0.81
52 Week High
$2.40
P/E
-0.71x
P/B
1.02x
P/S
1.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.23M
Earnings
-$18.27M
Gross Margin
26.2%
Operating Margin
-353.61%
Profit Margin
-349.5%
Debt to Equity
0.48
Operating Cash Flow
-$16M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NSPR Overview
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NSPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NSPR ($1.64) is undervalued by 26.99% relative to our estimate of its Fair Value price of $2.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NSPR ($1.64) is significantly undervalued by 26.99% relative to our estimate of its Fair Value price of $2.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NSPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NSPR due diligence checks available for Premium users.
Be the first to know about important NSPR news, forecast changes, insider trades & much more!
NSPR News
Valuation
NSPR fair value
Fair Value of NSPR stock based on Discounted Cash Flow (DCF)
Price
$1.64
Fair Value
$2.25
Undervalued by
26.99%
NSPR ($1.64) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NSPR ($1.64) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NSPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NSPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.71x
Industry
751.36x
Market
54.23x
NSPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
3.87x
NSPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NSPR's financial health
Profit margin
Revenue
$1.2M
Net Income
-$4.3M
Profit Margin
-343.5%
NSPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NSPR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.9M
Liabilities
$6.5M
Debt to equity
0.48
NSPR's short-term assets ($16.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NSPR's short-term assets ($16.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NSPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NSPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$4.4M
Financing
$0.0
NSPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NSPR vs Medical Device Stocks
Inspiremd Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.